277 related articles for article (PubMed ID: 32483276)
41. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
[TBL] [Abstract][Full Text] [Related]
42. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
[TBL] [Abstract][Full Text] [Related]
43. Inactivation of BRCA1 and BRCA2 in ovarian cancer.
Hilton JL; Geisler JP; Rathe JA; Hattermann-Zogg MA; DeYoung B; Buller RE
J Natl Cancer Inst; 2002 Sep; 94(18):1396-406. PubMed ID: 12237285
[TBL] [Abstract][Full Text] [Related]
44. Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Radosa MP; Häfner N; Camara O; Diebolder H; Mothes A; Winzer H; Jansen L; Dürst M; Runnebaum IB
Int J Gynecol Cancer; 2011 Nov; 21(8):1399-406. PubMed ID: 21897273
[TBL] [Abstract][Full Text] [Related]
45. Peripheral blood
Jung Y; Hur S; Liu J; Lee S; Kang BS; Kim M; Choi YJ
J Gynecol Oncol; 2021 Mar; 32(2):e23. PubMed ID: 33470065
[TBL] [Abstract][Full Text] [Related]
46. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
47. The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing.
Jones MA; Timms KM; Hatcher S; Cogan ES; Comeaux MS; Perry M; Morris B; Swedlund B; Elks CE; Lao-Sirieix P; Dearden S; Egile C; Brown JS; Harrington EA; Hodgson D; Stern M; Slavin TP; Mancini-DiNardo D
Genes Chromosomes Cancer; 2023 Oct; 62(10):589-596. PubMed ID: 37222498
[TBL] [Abstract][Full Text] [Related]
48. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
Zhang M; Liu G; Xue F; Edwards R; Sood AK; Zhang W; Yang D
Gynecol Oncol; 2016 Apr; 141(1):57-64. PubMed ID: 27016230
[TBL] [Abstract][Full Text] [Related]
49. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL
Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196
[TBL] [Abstract][Full Text] [Related]
50. Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
Blanc-Durand F; Tang R; Pommier M; Nashvi M; Cotteret S; Genestie C; Le Formal A; Pautier P; Michels J; Kfoury M; Hervé R; Mengue S; Wafo E; Elies A; Miailhe G; Uzan J; Rouleau E; Leary A
Clin Cancer Res; 2023 Aug; 29(16):3124-3129. PubMed ID: 37067532
[TBL] [Abstract][Full Text] [Related]
51. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
52. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
[TBL] [Abstract][Full Text] [Related]
53. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
54. Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.
de Jonge MM; Ruano D; van Eijk R; van der Stoep N; Nielsen M; Wijnen JT; Ter Haar NT; Baalbergen A; Bos MEMM; Kagie MJ; Vreeswijk MPG; Gaarenstroom KN; Kroep JR; Smit VTHBM; Bosse T; van Wezel T; van Asperen CJ
J Mol Diagn; 2018 Sep; 20(5):600-611. PubMed ID: 29936257
[TBL] [Abstract][Full Text] [Related]
55. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
56. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
57. Detection of
Concolino P; Capoluongo E
Expert Rev Mol Diagn; 2019 Sep; 19(9):795-802. PubMed ID: 31429350
[No Abstract] [Full Text] [Related]
58. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
Liu G; Yang D; Sun Y; Shmulevich I; Xue F; Sood AK; Zhang W
Pharmacogenomics; 2012 Oct; 13(13):1523-35. PubMed ID: 23057551
[TBL] [Abstract][Full Text] [Related]
59. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
[TBL] [Abstract][Full Text] [Related]
60. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
